Changes in management of mediastinal tumours following the surge of COVID-19 pandemic (Ongoing)

Posted On 2020-12-31 16:20:17



This series on “Changes in management of mediastinal tumours following the surge of COVID-19 pandemic” is edited by Dr. Giuseppe Banna, MD, Department of Medical Oncology, Portsmouth Hospitals NHS Trust, Portsmouth, UK and Dr. Alfredo Addeo, MD, Oncology Department, University Hospital Geneva, Geneva, Switzerland.

Giuseppe Banna, MD
Department of Medical Oncology, Portsmouth Hospitals NHS Trust, Portsmouth, UK

Giuseppe Banna is a Consultant Medical Oncologist for Lung and Urology tumours working at Portsmouth Hospitals NHS Trusts in Portsmouth, United Kingdom. In 2017 he was entitled with the Italian qualification as Associate Professor. He promoted numerous translational and clinical research studies as principal investigator, participating in national and European cancer research networks such as the EORTC, ETOP, BTOG and the Italian Meet-Uro. His clinical and scientific experience has been mostly focused on thoracic, urology/testicular cancer and prognostic and predictive biomarkers to immunotherapy. He is the coordinator of the Italian Association of Medical Oncology (AIOM)/Italian Germ Cell Cancer Group (IGG) guidelines for the testicular germ cell tumours. In 2011, he co-founded a no-profit organization (Medicare Onlus) aiming to support cancer patients and their families in the South of Italy. His professional objective is to offer the patient the best-individualized treatment and support.

Alfredo Addeo, MD
Oncology Department, University Hospital Geneva, Geneva, Switzerland

Dr. Alfredo Addeo is a senior oncologist at the Geneva University Hospital, Geneva Switzerland. Dr. Addeo received his training at the University of Turin (Italy) and completed a MD in oncology at the University school of medicine of Turin (Italy). Dr. Addeo has been working on thoracic malignancies since 2006 at the Geneva University Hospital. He has several publications on international peer-reviewed journal (JCO, Lancet Oncology, Annals of Oncology, Jama Oncology, etc). He is the lead for several translational research projects in his department: his main interests at the moment are liquid biopsy, ctDNA and TMB in thoracic malignancies.

Series outline:

1. Introduction to the series
Giuseppe Banna & Alfredo Addeo

2. High-dose chemotherapy for mediastinal non-seminoma, is still an option? 
Patrizia Giannatempo (Milan, Italy) & Simona Secondino (Pavia, Italy)

3. Repeat surgery for thymic tumors 
Andrea Billè (London, UK)

4. Systemic treatments for recurrent thymic tumours  
Paolo Zucali (Milan, Italy)

5. Postoperative adjuvant radiotherapy for non-small-cell lung cancer
Vieri Scotti & Emanuela Olmetto (Florence, Italy)

6. Targeted treatments for stage III NSCLC
Jordi Remon (Barcelona, Spain)

7. The use of liquid biopsy as diagnostic tool in thoracic tumours 
Valerio Gristina (Palermo, Italy) & Francesco Pepe (Naples, Italy)

8. Treatment of frail and elderly patients with thoracic tumours 
Sunil Daryanani (Somerset, UK) & Giuseppe Maltese (Surrey, UK)

9. Home-deliverable antitumoral treatments
Alex Friedlaender (Geneva, Switzerland) & Antonio Calles (Madrid, Spain)

10. Testing patients for Covid19 before and during treatments
Antonio Calles (Madrid, Spain)

11. Aerosol generating procedures during Covid19 
Alexander Hicks (Portsmouth, UK)


Disclosure:
The series “Changes in management of mediastinal tumours following the surge of COVID-19 pandemic” was commissioned by the editorial office, Mediastinum without any sponsorship or funding. Drs Giuseppe Banna and Alfredo Addeo are serving as the unpaid Guest Editor for the series.